Another IPF Drug Failure As Galecto Therapy Suffers Mid-Stage Flop

Firm To Focus On Liver After Lung Miss

Galecto’s decision to discontinue its idiopathic pulmonary fibrosis candidate after disappointing Phase IIb results represents the latest in a number of mid/late-stage failures to treat the disease.

Neon Light Sign Lungs Icon
• Source: Shutterstock

Galecto Inc. has become the latest company to fail at developing a new therapy for idiopathic pulmonary fibrosis (IPF) and has decided to concentrate its research efforts on severe liver diseases.

The switch in focus follows topline results from the Boston-based biotech's Phase IIb GALACTIC-1 trial evaluating GBO139, an inhaled galectin-3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.